To be eligible for the study, individuals must have had hyperkalaemia, possibly as a consequence of taking mineralocorticoid receptor antagonists (but not exclusively so); hence individuals that continued to use this drug would undergo more regular routine testing. This evidence concerns the gene NR3C2 and Hyperkalemia.